The synergy between THZ531 and AR antagonists may be driven by attenuated H3K27ac signaling on AR targets and intensive SE-associated apoptosis pathways, further suggesting the druggable value of CDK12 for PCa therapy. Here, AR is linked to posterior cortical atrophy.